SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453468.
  • 2
    Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991; 32: 429445.
  • 3
    Mattson RH, Cramer JA, Collins JF et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 1985; 313: 145151.
  • 4
    UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 11141117.
  • 5
    US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993; 43: 22922298.
  • 6
    Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994; 35: 795801.
  • 7
    Dougherty JA, Rhoney DH. Gabapentin: a unique anti-epileptic agent. Neurol. Res. 2001; 23: 821829.
  • 8
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489501.
  • 9
    French JA. Proof of efficacy trials: endpoints. Epilepsy Res. 2001; 45: 5356.
  • 10
    Hirotsu C. Isotonic inference. In : ArmitageP, ColtonT (eds). Encyclopedia of Biostatistics, Vol. 3. John Wiley & Sons, New York, 1998; 2107–2115.
  • 11
    Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drugs, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J. Biol. Chem. 1996; 271: 57685776.
  • 12
    Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998; 29: 233249.
  • 13
    French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 12521260.
  • 14
    McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994; 44: S17S22.
  • 15
    Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series. Treatment of epilepsy. Epilepsy Behav. 2001; 2 (Suppl.): A1A50.
  • 16
    French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 12611273.
  • 17
    Salas-Humara C, Weintraub D, Buchsbaum R et al. Comparative incidence of rash related to twelve antiepileptic drugs: results from the Columbia antiepileptic drug database. Program and Abstracts of the American Academy of Neurology 56th Annual Meeting, San Francisco, California, Abstract S41.003, 2004.
  • 18
    Weintraub D, Buchsbaum R, Spencer HT et al. Psychiatric side effects of the newer antiepileptic drugs: results from the Columbia antiepileptic drug database. Program and Abstracts of the American Academy of Neurology 56th Annual Meeting, San Francisco, California, Abstract P04.085, 2004.